Adherex Technologies (NASDAQ:FENC) Releases Earnings Results, Beats Expectations By $0.03 EPS

Adherex Technologies (NASDAQ:FENC) announced its earnings results on Thursday. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03, Zacks reports. Adherex Technologies had a negative return on equity of 183.18% and a negative net margin of 22.62%.The business had revenue of $15.11 million for the quarter, compared to analyst estimates of $13.90 million.

Here are the key takeaways from Adherex Technologies’ conference call:

• Fennec reported Q1 2026 net product sales of $15.1 million, up about 73% year over year, marking the sixth consecutive quarter of sales growth under the current commercial leadership.
• The company said its commercial push is gaining traction after launching Project Ignite, expanding the field force to 14 new territories and 4 frontline managers and increasing target prescribers from about 1,300 to more than 5,000.
• Operational metrics improved meaningfully, including a 48% quarter-over-quarter increase in completed infusions through Fennec HEARS, conversion rates reaching the company’s 80% benchmark, and adherence running around 80%.
• Management highlighted growing clinical interest in PEDMARK beyond pediatrics, including three investigator-initiated studies and four ASCO abstracts, with potential expansion into AYA and adult patient populations and new tumor types.
• Fennec ended the quarter with $40.1 million in cash and said it generated positive cash flow in Q1, but it also expects Q2 ending cash to be lower and noted it does not anticipate receiving the German milestone payment from partner Norgine.

Adherex Technologies Trading Up 36.5%

Adherex Technologies stock traded up $2.47 during midday trading on Thursday, hitting $9.24. The stock had a trading volume of 2,268,189 shares, compared to its average volume of 177,649. The stock has a market cap of $319.16 million, a P/E ratio of -27.18 and a beta of 0.91. Adherex Technologies has a 12 month low of $5.65 and a 12 month high of $9.92. The business has a fifty day moving average price of $6.89 and a 200 day moving average price of $7.56.

Insiders Place Their Bets

In related news, Director Rosty Raykov sold 10,781 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $6.47, for a total value of $69,753.07. Following the completion of the sale, the director directly owned 121,451 shares of the company’s stock, valued at $785,787.97. The trade was a 8.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.73% of the stock is currently owned by corporate insiders.

Institutional Trading of Adherex Technologies

An institutional investor recently bought a new position in Adherex Technologies stock. AQR Capital Management LLC acquired a new stake in Adherex Technologies Inc. (NASDAQ:FENC) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,897 shares of the company’s stock, valued at approximately $66,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analyst Ratings Changes

FENC has been the topic of a number of analyst reports. Zacks Research lowered Adherex Technologies from a “hold” rating to a “strong sell” rating in a research report on Wednesday, March 25th. Wedbush reaffirmed an “outperform” rating and set a $13.00 target price on shares of Adherex Technologies in a research report on Thursday, April 16th. Wall Street Zen lowered Adherex Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, April 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adherex Technologies in a research report on Tuesday, April 21st. Finally, B. Riley Financial initiated coverage on Adherex Technologies in a research report on Thursday, February 12th. They set a “buy” rating and a $16.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.80.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.